Holen Sie sich die Stockscreener-App
12.42
0.00%
0.00
Handel nachbörslich:
12.36
-0.06
-0.48%
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal rated buy in new research coverage at UBS as growth pipeline expands - MSN
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus - MSN
Is Amneal Pharmaceuticals (AMRX) Poised for Growth After a Strong Q1 2026 - Kavout
A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.6% Gain -- G - GuruFocus
A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.6% Gain -- GF Value $7.57 vs Price $12.21 - GuruFocus
Stronger Q1 Profitability And Reaffirmed Outlook Could Be A Game Changer For Amneal (AMRX) - simplywall.st
Amneal Pharmaceuticals Is Maintained at Overweight by Barclays - Moomoo
Amneal Shareholders Back Board, Pay and Auditor at Meeting - TipRanks
Should value investors buy Amneal Pharmaceuticals (AMRX) stock? - MSN
Why Amneal Pharmaceuticals (AMRX) is a top growth stock for the long term - MSN
Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Amneal Pharmaceuticals, Inc.Class A Common Stock (Nasdaq:AMRX) Stock Quote - The Chronicle-Journal
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
Amneal Pharmaceuticals among major pharmaceutical companies under Federal Investigation - The Indian Panorama
AMRX Should I Buy - Intellectia AI
3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX) - Yahoo Finance
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock? - Yahoo Finance
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
Amneal Pharmaceuticals' (NASDAQ:AMRX) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance
AMRX growth drivers: Generics, biosimilars, and Crexont - MSN
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness - Sahm
Amneal (AMRX) director Deborah Autor sells 34,819 shares at $12.94 avg - Stock Titan
[144] Amneal Pharmaceuticals, Inc. SEC Filing - Stock Titan
Do options traders know something about Amneal stock we don't? - MSN
Amneal (AMRX) Q3 2025 Earnings Call Transcript - AOL.com
AMRX SEC FilingsAmneal Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Amneal Pharmaceuticals (AMRX) Profit Rebound Challenges Concerns Over Earnings Quality - Sahm
[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director BUCHI J KEVIN - Moomoo
Amneal (NYSE: AMRX) director exercises 34,819 RSUs and receives new grant - Stock Titan
Amneal (NYSE: AMRX) director settles RSUs, now holds 128,479 shares - Stock Titan
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director George Jeffrey P. - Moomoo
Amneal (AMRX) director Jeffrey George exercises 34,819 RSUs, receives 19,824 new units - Stock Titan
Amneal (AMRX) director exercises RSUs, now holds 260,252 shares - Stock Titan
Director boosts stake with 34,819 shares in Amneal (NYSE: AMRX) - Stock Titan
Amneal (NYSE: AMRX) director exercises 48,747 RSUs and receives 30,837-unit grant - Stock Titan
Amneal (NYSE: AMRX) director converts RSUs to shares and gets new grant - Stock Titan
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised) - Yahoo Finance
Amneal Pharmaceuticals Q1 2026 & M&A announcement Earnings Call Transcript - MarketBeat
Amneal Pharmaceuticals (NASDAQ: AMRX) posts Q1 profit surge and inks $375M Kashiv acquisition - Stock Titan
Drugmaker Amneal posts $62M profit as specialty-drug sales rise 23% - Stock Titan
Amneal (NASDAQ: AMRX) investors back directors, say-on-pay and EY as auditor - Stock Titan
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, vs. FactSet Est of $0.17 - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, vs. FactSet Est of $719.7M - marketscreener.com
Amneal (NASDAQ: AMRX) Q1 2026 profit soars as margins rise and guidance held - Stock Titan
Amneal Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, Vs. FactSet Est of $719.7M - Moomoo
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, Vs. FactSet Est of $0.22 - Moomoo
Number of shareholders of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
1.92%
4.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):